Ralinepag for Pulmonary arterial hypertension
The FDA is expected to decide on Ralinepag for Pulmonary arterial hypertension by June 24, 2027, under a NDA from United Therapeutics.
What is being decided
United Therapeutics has a NDA under FDA review for Ralinepag in Pulmonary arterial hypertension. Once-daily oral prostacyclin receptor agonist.
Who this decision matters to
Pulmonary arterial hypertension is a rare disease characterized by abnormally high blood pressure in the pulmonary arteries, causing progressive heart and lung damage. The disease involves vasoconstriction, thrombosis, and vascular remodeling. Multiple disease-modifying therapies targeting different pathways have improved survival and quality of life.
Prevalence: 1-2 per million people. See our full Pulmonary Arterial Hypertension page for current treatments, recruiting trials, and community resources.
What each outcome would mean
An approval starts a second race rather than ending the first one: specialty pharmacy setup, insurance review, and patient assistance typically take weeks even when everything goes right. Our guide to the 90 days after a rare disease approval explains the timeline and the moves families can make on day 1.
A complete response letter would mean the FDA declined to approve in the application's current form. CRLs are often about manufacturing or data presentation rather than efficacy, and resubmission is common. Either way, this page updates with the outcome and what it means.
Where Pulmonary Arterial Hypertension treatment stands today
The treatment approach for pulmonary arterial hypertension has shifted significantly toward early, aggressive combination therapy targeting multiple pathways at once, and current trials are building on that momentum. Researchers are testing new pulmonary vasodilators and antiproliferative agents that go beyond the established endothelin, nitric oxide, and prostacyclin pathways. Most guidelines now recommend starting combination therapy right at diagnosis rather than waiting, so if you have PAH, early action matters. Regular monitoring through right heart catheterization helps your care team fine-tune your regimen over time. The Pulmonary Hypertension Association is an excellent resource for finding trials in your area, and if you have idiopathic or familial PAH, genetic testing can provide valuable information about your prognosis and potential trial eligibility.
Meanwhile, 368 Pulmonary Arterial Hypertension trials are recruiting
Whatever the FDA decides here, research on Pulmonary Arterial Hypertension does not stop. A few currently enrolling studies, US sites first:
Other drugs Trial Friend tracks for Pulmonary Arterial Hypertension
Get notified when new pulmonary-arterial-hypertension trials open or existing trials change status, add sites, or update eligibility.
Frequently asked questions
When will the FDA decide on Ralinepag?
The FDA's target decision date (PDUFA date) for Ralinepag in Pulmonary arterial hypertension is June 24, 2027, disclosed by United Therapeutics. The agency can act before this date and occasionally runs past it.
What is Ralinepag being reviewed for?
United Therapeutics submitted a NDA for Ralinepag in Pulmonary arterial hypertension. Once-daily oral prostacyclin receptor agonist.
What happens after the Ralinepag decision?
If approved, availability is not immediate: specialty pharmacy setup, insurance review, and patient assistance typically take weeks even when everything goes right. If the FDA issues a complete response letter, the application was not approved in its current form; CRLs are often about manufacturing or data presentation rather than efficacy, and sponsors frequently resubmit. This page updates with the outcome either way.
Where this date comes from
The FDA does not publish PDUFA dates; companies disclose them. This one comes from United Therapeutics press release. Dates can move, and the FDA can act early or late. This page rechecks against our calendar, which is re-verified weekly.